Meerkat raise some good points in his last post. The only remarks I would make is that the present Vax trials were given the green light (paid and their direction within AHZ ) by the old board.
Wayne certainly now has to provide a clear direction of the Vax section and how it will be funded if retained. He already mentioned in the webinar that it will be by external means so I believe he agrees with what has already been said that requires to be a separate entity in many aspects of the business.
WP has initially focused on the management, Malaga manufacturing and sales side of the medical devices aspects within AHZ and I believe now he will focus in correcting the Vax side of things.
Haplo
Ann: Admedus Releases Results of HSV-2 Phase IIa Study, page-277
-
- There are more pages in this discussion • 74 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$11.30 |
Change
-0.650(5.44%) |
Mkt cap ! $238.8M | |||
| Open | High | Low | Value | Volume |
| $11.71 | $11.83 | $11.24 | $346.8K | 29.94K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 90 | $11.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $11.50 | 50 | 1 |
View Market Depth
| Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |